Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sarepta And Roche Press Ahead With Elevidys Filing Despite Duchenne Trial Miss

Executive Summary

The Phase III EMBARK study has fallen short on its primary endpoint – but Sarepta believes the trial has otherwise produced robust data, and believes a full US approval is justified.

You may also be interested in...

How Roche Plans To Stay Ahead In MS And Catch Up In Alzheimer’s

Neuroscience is increasingly a focus for the Swiss pharma giant, and it believes it can stay ahead in multiple sclerosis with fenebrutinib, while making up lost ground in with two key candidates in Alzheimer’s disease.

A Strong Launch For Sarepta’s Elevidys, But Future Hinges On FDA Decision

Strong demand from physicians and families of boys with Duchenne has seen a rapid take-off in sales of the $3.2m gene therapy – but the FDA will have the final say on the product's future after a failed Phase III study.

Don’t Count Pfizer Out In DMD

Pfizer reminded investors it still has a gene therapy in Phase III development for Duchenne muscular dystrophy after Sarepta’s disappointing Phase III readout.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts